Investor Relations About 20/20 GeneSystems 20/20 GeneSystems, Inc. is a U.S. based privately held corporation based in Maryland. Investment in the company is currently open for Angel, Private and Institutional investors. Investors are invited to review our current Wefunder investment campaign by clicking the link below. Go to Wefunder Campaign 20/20 GeneSystems is offering investments […]
Our Team Jonathan Cohen Founder, CEO Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for
Investing with 20/20 Investors Welcome! 20/20 GeneSystems is a U.S. based private corporation located in Maryland. Investment opportunities are currently available and as a Reg A+ company, anyone can become a shareholder in our company. We have raised more than $5 million in equity crowd funding, making us one of the most successful crowd-funding life
The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders.
Welcome to 20/20 GeneSytems Read More »
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.
